Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Y332
- Development stage
- Phase 1
- Lead developer
- Wuhan YZY Biopharma
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Y332 is a bispecific antibody (BsAb) developed by Wuhan YZY Biopharma Co., Ltd., utilizing their proprietary Y-body platform. It is designed as a T-cell engager that simultaneously targets CD70, a member of the tumor necrosis factor (TNF) receptor superfamily often overexpressed in various malignancies, and CD3, a component of the T-cell receptor complex. By bridging T cells and CD70-expressing tumor cells, Y332 facilitates the activation and redirection of cytotoxic T lymphocytes to eliminate cancer cells. It is primarily being investigated for the treatment of advanced solid tumors, including renal cell carcinoma and other CD70-positive cancers, particularly in patients who have failed standard therapies.
- Other names
- CD3 x CD70 bispecific antibodyCD-3 x CD70 bispecific antibodyCD 3 x CD70 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on Y332.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Y332.